Acumen updates corporate presentation with new EBD data, ACU234 pipeline addition

Acumen Pharmaceuticals, Inc.

Nonclinical murine brain exposure data for Enhanced Brain Delivery program presented at CTAD 2025 included.
Updated fluid biomarker data from Phase 1 INTERCEPT-AD study added to presentation.
ACU234, a new candidate under the EBD program, now listed in pipeline.
Presentation posted on company website for use in conferences and communications.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.